...
首页> 外文期刊>European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology >Persistent angina pectoris in ischaemic cardiomyopathy: Increased rehospitalization and major adverse cardiac events
【24h】

Persistent angina pectoris in ischaemic cardiomyopathy: Increased rehospitalization and major adverse cardiac events

机译:缺血性心肌病的持久性心绞痛:再生生长和主要不良心脏事件

获取原文
获取原文并翻译 | 示例
           

摘要

Aims The impact of refractory angina pectoris (AP) in patients with ischaemic cardiomyopathy (ICM) is unknown. We investigated the characteristics and outcomes of ICM patients with persistent AP following cardiac catheterization. Methods and results Patients who underwent coronary angiography at Duke from 2000 to 2009 with an EF <40% and ICM with persistent AP were compared with similar patients without persistent AP. Persistent AP was defined by patient report of ischaemic symptoms within 1 year of index catheterization. Time-to-event was examined using Kaplan-Meier or cumulative incidence and Cox proportional hazards modelling methods for death/myocardial infarction (MI)/revascularization [i.e. major adverse cardiac events (MACE)], death/MI, death, and cardiovascular death/hospitalization. Of 965 ICM patients, 298 (31%) had persistent AP. These patients were younger and had more previous revascularization than patients without persistent AP. Both groups had high use of aspirin, beta-blockers, ACE inhibitors, and statins, but modest nitrate use. Over a median follow-up of >5 years, patients with persistent AP had increased rates of MACE, and cardiovascular death/hospitalization compared with patients without persistent AP [5-year cumulative event rates of 53% vs. 46% (P = 0.013) and 73% vs. 60% (P < 0.0001), respectively], but similar rates of death (P = 0.59) and death/MI (P = 0.50). After multivariable adjustment, persistent AP remained associated with increased MACE [hazard ratio (HR) 1.30; 95% confidence interval (CI) 1.08-1.57], and cardiovascular death/ hospitalization (HR 1.36; 95% CI 1.14-1.62). Conclusion Persistent AP is common despite medical therapy in patients with ICM and is independently associated with increased long-term MACE and rehospitalization. Future prospective studies of persistent AP in ICM patients are warranted.
机译:旨在令人未知的缺血性心肌病(ICM)难治性心绞痛(AP)对患者的影响是未知的。我们调查了心脏导管插入术后持久性AP患者的ICM患者的特征和结果。将Duke冠状动脉造影在2000〜2009年与EF <40%和ICM的患者接受冠状动脉造影的方法和结果与持久性AP的类似患者进行比较。持久性AP由指数导尿率1年内的缺血性症状的患者报告定义。使用Kaplan-Meier或累积发病率和Cox比例危害模拟方法检查死亡/心肌梗死(MI)/血运重建的累积事件[即,主要不良心脏事件(术术)],死亡/ MI,死亡和心血管死亡/住院治疗。 965名ICM患者,298例(31%)有持久的AP。这些患者年轻,并且比没有持久性AP的患者更年轻,更先前的血运重建。两组均具有高利用阿司匹林,β-阻滞剂,ACE抑制剂和他汀类药物,但使用适度的硝酸盐。在中间后续随访> 5年,与没有持久性AP的患者相比,持久性AP的患者增加了术士和心血管死亡/住院的患者[5年累计事件率为53%,P = 0.013 )和73%与60%(P <0.0001),但死亡率相似(p = 0.59)和死亡/ mi(p = 0.50)。经过多变量调节后,持久性AP仍然与MACE增加相关[危险比(HR)1.30; 95%置信区间(CI)1.08-1.57]和心血管死亡/住院(HR 1.36; 95%CI 1.14-1.62)。结论持久性AP虽然患有ICM患者的医疗治疗,但与长期立柱和再生生长的医疗治疗有关。认定ICM患者持久性AP的未来前瞻性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号